RxDoctor Payments Data

Nancy McDowell

Nurse Practitioner · Corpus Christi, TXNPI 1710234398

Payments from drug & device makers

$12,442in general payments, 2019–2025

Across 699 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$3K
  • Lilly USA, LLC$2K
  • AbbVie$718
  • Pfizer$420
  • Amgen$396
  • Amarin Pharma, Inc.$395
  • plus $6K from 44 others

What the payments were for

  • Food & beverage$12,24398%
  • Education$1992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,442 in reported general payments places this provider in the 95th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$77,331
Medicare patients
169
Services billed
1,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide116$145,748
MounjaroTirzepatide98$118,122
TrulicityDulaglutide53$97,225
FarxigaDapagliflozin Propanediol41$46,725
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$33,715
JardianceEmpagliflozin27$32,855
RybelsusSemaglutide14$29,273
MyrbetriqMirabegron42$26,638
XareltoRivaroxaban14$15,387
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$14,782
EliquisApixaban11$8,723
Xigduo XrDapaglifloz Propaned/Metformin11$7,557
Praluent PenAlirocumab12$5,978
Janumet XrSitagliptin Phos/Metformin Hcl13$5,760
Rosuvastatin Calcium291$3,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,574$215,347151 claims
Novo NordiskOzempic, Rybelsus$2,538$175,021130 claims
AstraZenecaFarxiga$367$46,72541 claims
GSKTrelegy Ellipta$391$33,71531 claims
Boehringer IngelheimJardiance$374$32,85527 claims
Astellas Pharma US IncMyrbetriq$295$26,63842 claims
Johnson & JohnsonXarelto$213$15,38714 claims
PfizerEliquis$420$8,72311 claims
MerckJanumet Xr$194$5,76013 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$2,445183 claims
AbbVieSynthroid$718$1,02923 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →